| Stephen Alexander | University of Nottingham | Biochemistry and pharmacology of GPCR, particularly cannabinoid and orphan receptors. Historically, also metabotropic glutamate receptors. Chair of NC-IUPHAR. SE of BJP. Other stuff. |
| Paolo Annibale | University of St Andrews | |
| Despoina Aslanoglou | University of Portsmouth | GPCRs signaling and molecular pharmacology, catecholamine receptors, CNS and pancreas |
| Aisah Aubdool | Queen Mary University of London | |
| Chris Bailey | University of Bath | Electrophysiology, in vivo behaviour |
| Imre Berger | University of Bristol | |
| Steve Briddon | University of Nottingham | Molecular pharmacology of GPCRs, Imaging and Spatiotemporal dynamics of receptors, Fluorescence Fluctuation Spectroscopy, Fluorescent ligands |
| Lloyd Bridge | University of the West of England | Mathematical modelling, Mathematical pharmacology, Receptor theory, PK/PD modelling, G protein-coupled receptors |
| David Bulmer | University of Cambridge | Sensory nerves, GPCRs |
| Davide Calebiro | University of Birmingham | |
| Meritxell Canals | University of Nottingham | BRET/FRET/Imaging, Protein protein interactions, opioid receptors, pain transmission and modulation, chemokine receptors |
| John Challiss | University of Leicester | Molecular pharmacology of GPCRs. Signal transduction. GPCR regulation by GRKs and arrestin proteins |
| Samantha Cooper | University of Nottingham | Structural Biology, Synthetic Biology, Protein Complexes |
| Robin Corey | University of Bristol | Molecular modelling, molecular dynamics, lipids, pharmacology |
| Margaret Cunningham | University of Strathclyde | GPCR membrane trafficking, molecular pharmacology, dimerisation, |
| Anthony Davenport | University of Cambridge | Role of endothelin, apelin and relaxin receptors in the human cardiovascular system (eg recent paper Williams et al. Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor. Nat Commun. 2024 15:10714. doi: 10.1038/s41467-024-55381-w). Member of IUPHAR Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) Database Executive Committee with responsibility for orphan GPCRs. |
| Giuseppe Deganutti | Coventry University | Molecular modelling; biomolecular simulations; computational medicinal chemistry; class A and B GPCR |
| Caroline Gorvin | University of Birmingham | Signalling and trafficking of calcium-sensing receptor (CaSR), Genetic mutations in CaSR and signalling pathway, Metabolic GPCR signalling |
| Raphael Haider | University of Nottingham | BRET biosensors, arrestins, GRKs |
| Aylin Hanyaloglu | Imperial College London | GPCR membrane trafficking, compartmentalised GPCR signalling, dimerisation, single molecule imaging, endocrine GPCRs, female reproductive health and pregnancy, metabolite-sensing GPCRs. |
| Stephen Hill | University of Nottingham | |
| James Hislop | University of Aberdeen | Endocytic Trafficking, Signalling, Structure activity relationship, arrestin, desensitisation, downregulation. |
| Brian Hudson | University of Glasgow | Molecular pharmacology, GPCR technology development, GPCR drug discovery, genetically encoded biosensors, BRET, fluorescent ligand binding, metabolic disorders, diabetes, adipocytes, macrophages, in vitro 3D culture |
| Andrew Irving | University of Northampton | Molecular neuroscience |
| Kim Jonas | King’s College London | |
| Ben Jones | Imperial College London | |
| Barrie Kellam | University of Nottingham | Synthetic and Medicinal Chemistry |
| Eamonn Kelly | University of Bristol | Molecular pharmacology of GPCRs, particularly opioid receptors. ligand binding, signalling assays (BRET), in silico modelling |
| Laura Kilpatrick | University of Nottingham | BRET, Fluorescence Correlation Spectroscopy, adenosine receptors, P2Y2R, CXCR4, GPCR-RTK interactions |
| Graham Ladds | University of Cambridge | BRET, kinetics, computational modelling, agonist bias, RAMPs |
| Brian Lam | University of Cambridge | |
| Rob Lane | University of Nottingham | Molecular and analytical pharmacology, dopamine receptors, kinetics |
| Sam Lockhart | Queen’s University Belfast | |
| Isabella Maiellaro | University of Nottingham | Drosophila , FRET-based approaches, high throughput assay, behaviour assay, super resolution microscopy |
| Maria Marti-Solano | University of Cambridge | Computational Pharmacology, Structural Bioinformatics, Pharmacogenomics, Context-specific Receptor Signalling, Systems Biology |
| Peter McCormick | University of Liverpool | Molecular Pharmacology and Drug Discovery of GPCRs, GPCR oligomers |
| Graeme Milligan | University of Glasgow | GPCR pharmacology, structure and regulation. |
| Shailesh Mistry | University of Nottingham | Synthetic organic and medicinal chemistry. The design, synthesis, purification and characterisation of small molecules in the pursuit of novel drug discovery or the development of tool compounds. In particular, a focus on allosteric, orthosteric and bitopic ligands for G Protein-coupled receptors and other proteins. Keywords: Medicinal chemistry, drug discovery, chemical biology, fluorescent ligands, allosteric ligand design, orthosteric ligand design. |
| Anja Mueller | University of East Anglia | Chemokine Receptors, GPCR signalling, chemotaxis |
| Stuart Mundell | University of Bristol | G protein-coupled receptor function and signalling in atherothrombosis. |
| Fiona Murray | University of Aberdeen | |
| Daniel Nietlispach | University of Cambridge | GPCR conformational dynamics, NMR spectroscopy, biophysical characterisation |
| Sahil Patel | University College London | |
| Chloe Peach | University of Nottingham | Spatiotemporal Dynamics, Signalling, Endocytosis, Ligand Binding, Receptor Tyrosine Kinases, Glycoproteins, Neurotrophic Signal Transduction |
| James Pease | Imperial College London | Chemoattractant receptors, chemotaxis, small molecule antagonists |
| Nicole Perry-Hauser | University of Glasgow | Adhesion G protein-coupled Receptors, Signal Transduction, Neuropsychiatric Disorders |
| Bianca Plouffe | Queen’s University Belfast | Compartmentalised G protein signalling, Gq signalling, BRET, nanoBiT, FRET, signal bias, allosteric modulators |
| David Poyner | Aston University | Molecular pharmacology of family B GPCRs, especially CGRP and related receptors |
| Sarah Rouse | Imperial College London | |
| Maria Shchepinova | University of Bath | GPCRs proximity proteomics |
| Julie Sanchez | University of Nottingham | Opioid receptors, Chemokine receptors, GPCR-TRP channel modulation, BRET |
| Hardip Sandhu | Coventry University | Vascular Therapy-induced cardiovascular injury (TICvI) model exploiting the G-protein coupled receptors (GPCRs) signalling: For >17 years, I have focused on investigating therapy-induced cardiovascular injury by applying my expertise in safety pharmacology and cardiovascular diseases and injury development to address TICvI. I am building on my “proof-of-principle” preliminary work presented briefly in the projects described above and aim to deliver TICvI screening models that will aid the PhamaIndustry in identifying cardiovascular adverse effects of their candidate drugs, allowing them to make changes and avoid wasting valuable resources developing a drug candidate that would ultimately fail in the clinic due to its cardiovascular adverse effects. The TICvI screening models could also be used in a healthcare setting to monitor patients who are undergoing therapy known to be associated with cardiovascular adverse effects. For decades, the study of vascular TICvI in non-clinical toxicity studies has been a challenging issue for the PharmaIndustry, as currently there are no translatable specific and sensitive vascular TICvI screening platforms available. This novel project focuses on the involvement of key regulators of cardiovascular disease development during vascular TICvI, namely the GPCRs. The GPCRs belong to the largest family of membrane receptors that are targeted by approximately 35% of FDA-approved drugs. Pioneering work for this project is revealing that GPCRs could prove to be unexplored common mediators of vascular TICvI development, and therefore the vascular TICvI GPCR-based model could be used to screen candidate drugs for TICvI adverse effects. The Intellectual Property of this project is currently being explored together with PhamaIndustry partners. |
| Luke Schembri | University of Nottingham | Organic and Analytical chemistry. Medicinal chemistry including fluorescent GPCR ligands. |
| Elena Seiradake | University of Oxford | Structural biology, protein engineering, cell biology, neurobiology |
| Ewan Smith | University of Cambridge | Acid sensing, Pain neurobiology, Naked mole-rat physiology |
| Leanne Stokes | University of East Anglia | Purinergic receptors, cell signalling, drug discovery |
| Chris Tate | MRC Laboratory of Molecular Biology | Protein engineering of GPCRs and G proteins, GPCR expression in stable inducible mammalian cell lines and the baculovirus expression, Purification to mg amounts, Biophysical characterisation (SPR, BLI, SEC-MALS), Structure determination by electron cryomicroscopy (cryo-EM) |
| Dawn Thompson | University of Aberdeen | Immunopharmacology, Neuropharmacology, Metabolic Health, Cardiovascular Disease, Addiction |
| Irina Tikhonova | Queen’s University Belfast | Molecular modelling, computer-aided drug design, data analytics |
| Andrew Tobin | University of Glasgow | GPCR signalling, physiology including central and peripheral processes, drug discovery and translational science |
| Alejandra Tomas | Imperial College London | My research is focused on the study of the spatiotemporal regulation of signalling and mechanisms of signal compartmentalisation of the glucagon receptor family in pancreatic islets and other metabolically relevant cell types to control blood glucose levels, with direct application to the development of novel Type 2 Diabetes (T2D), obesity, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) therapies. I am working in projects related to the study of cell subtype and/or subcellular compartmentalisation of signalling, inter-organelle communication, receptor-driven lipid detoxification, control of receptor post-translational modifications (currently phosphorylation and SUMOylation), and development of allosteric modulators targeting receptor lipid binding sites, as well as molecular characterisation of receptor gain- and/or loss-of-function natural coding variants to develop personalised therapeutic strategies. I use molecular cell biology techniques such as CRISPR/Cas9 gene editing, high-resolution/super-resolution fluorescence and electron microscopy imaging, multiomic analyses, pharmacology methods, and cell type-specific/subcellular biosensor-based assays to characterise receptor signalling outputs from cell lines and primary tissues/islets, as well as studying the in vivo effects on glucose handling from transgenic mice and/or mouse models of diet-induced diabetes. |
| Dmitry Veprintsev | University of Nottingham | Structural and biophysical pharmacology of GPCRs. ML. Protein engineering. Advances ligand engagement and signalling assays. |
| Jeanette Woolard | University of Nottingham | Cardiovascular physiology, pharmacology – adenosine receptors, endothelin receptors |
| Stephen Wren | Kingston University London | Drug discovery, Medicinal chemistry |
